Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir
and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic
hepatitis C genotype 1b Infection
Details
Lead Sponsor:
Sang Gyune Kim
Collaborators:
Bristol-Myers Squibb Ewha Womans University Mokdong Hospital Gachon University Gil Medical Center Hanyang University Seoul Hospital Inha University Hospital Korea University Seoul National University Boramae Hospital Severance Hospital